Researchers have developed a skin-based test that can detect misfolded tau proteins specific to progressive supranuclear palsy (PSP), offering a faster, more accurate diagnosis than current methods. This breakthrough could improve patient assignment to clinical trials and eventually guide targeted, precision treatments.